Akums Drugs

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE09XN01023
NSEID: AKUMS
BSEID: 544222
View on NSE | View on BSE

INR

520.55

6.3 (1.23%)

BSENSE

May 21

BSE+NSE Vol: 97.88 k

{
  "main_header": {
    "sid": 10039335,
    "name": "Akums Drugs",
    "stock_name": "Akums Drugs",
    "full_name": "Akums Drugs & Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/akums-drugs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "520.55",
    "chg": 6.3,
    "chgp": "1.23%",
    "dir": 1,
    "prev_price": "514.25",
    "mcapval": "8,193.14 Cr",
    "mcap": "Small Cap",
    "scripcode": "544222",
    "symbol": "AKUMS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE09XN01023",
    "curr_date": "May 21",
    "curr_time": "",
    "bse_nse_vol": "97.88 k",
    "exc_status": "Active",
    "traded_date": "May 21, 2026",
    "traded_date_str": "2026 05 21",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/akums-drugs-10039335-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Akums Drugs & Pharmaceuticals Ltd Shows Mildly Bullish Momentum Amid Mixed Technical Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/akums-drugs-pharmaceuticals-ltd-shows-mildly-bullish-momentum-amid-mixed-technical-signals-3998186",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AkumsDrugsPharm_technicaldot_3998186.png",
        "date": "2026-05-19 08:07:40",
        "description": "Akums Drugs & Pharmaceuticals Ltd has exhibited a subtle shift in price momentum, transitioning from a bullish to a mildly bullish technical stance. Recent indicator signals, including MACD, RSI, and moving averages, suggest a nuanced market sentiment as the stock navigates key resistance levels within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Akums Drugs & Pharmaceuticals Ltd: Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/akums-drugs-pharmaceuticals-ltd-valuation-shifts-signal-renewed-price-attractiveness-3996181",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AkumsDrugsPharm_valuationdot_3996181.png",
        "date": "2026-05-18 08:03:18",
        "description": "Akums Drugs & Pharmaceuticals Ltd has witnessed a significant improvement in its valuation parameters, shifting from an 'attractive' to a 'very attractive' grade, despite a recent dip in share price. This repositioning comes amid a challenging sector environment and evolving market dynamics, prompting investors to reassess the stock’s price attractiveness relative to its peers and historical benchmarks."
      },
      {
        "title": "Akums Drugs & Pharmaceuticals Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/akums-drugs-pharmaceuticals-ltd-is-rated-hold-3994088",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AkumsDrugsPharm_mojoScore_3994088.png",
        "date": "2026-05-16 10:10:03",
        "description": "Akums Drugs & Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 10 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Akums Drugs Declines 7.15%: Mixed Quarterly Results and Rising Costs Weigh on Stock",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/akums-drugs-declines-715-mixed-quarterly-results-and-rising-costs-weigh-on-stock-3993776",
        "imagepath": "",
        "date": "2026-05-16 10:01:53",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>May 11:</strong> Stock opens at Rs.539.55, down 3.17% amid broad market weakness</p>\n                    <p><strong>May 13:</strong> Share rebounds 2.45% to Rs.540.95 following stabilising quarterly outlook</p>\n                    <p><strong>May 14:</strong> Q4 FY26 results reveal strong operational metrics but margin pressures</p>\n                    <p><strong>May 15:</strong> Mixed quarterly performance reported; stock closes at Rs.517.35, down 1.72%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.557.20</div></div>\n                    <div class=\"sta..."
      },
      {
        "title": "Are Akums Drugs & Pharmaceuticals Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-akums-drugs-pharmaceuticals-ltd-latest-results-good-or-bad-3993380",
        "imagepath": "",
        "date": "2026-05-15 19:29:06",
        "description": "Akums Drugs & Pharmaceuticals Ltd's latest financial results for Q4 FY26 present a mixed picture of operational performance. The company reported a net profit of ₹84.61 crores, reflecting a quarter-on-quarter increase of 27.58%, indicating a recovery in profitability compared to the previous quarter. However, this figure represents a significant year-on-year decline of 42.68%, highlighting ongoing challenges in maintaining profitability over a longer timeframe.\n\nNet sales for the quarter stood at ₹1,157.87 crores, which was essentially flat compared to the previous quarter, showing a minor decrease of 0.15%. In contrast, year-on-year sales demonstrated a more positive trend, with a growth of 9.69% from ₹1,055.55 crores in the same quarter last year. This suggests that while sequential sales performance has stagnated, there is stable demand for the company's contract manufacturing services when viewed over a..."
      },
      {
        "title": "Akums Drugs & Pharmaceuticals Ltd Reports Mixed Quarterly Performance Amid Margin Pressures",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/akums-drugs-pharmaceuticals-ltd-reports-mixed-quarterly-performance-amid-margin-pressures-3992943",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AkumsDrugsPharm_fintrenddot_3992943.png",
        "date": "2026-05-15 15:00:38",
        "description": "Akums Drugs & Pharmaceuticals Ltd reported a flat financial trend for the quarter ended March 2026, marking a stabilisation after previous declines. Despite this, the company demonstrated notable strength in operating margins and profitability metrics, even as net profit contracted over the nine-month period. This mixed performance has led to an upgrade in its Mojo Grade from Sell to Hold, reflecting cautious optimism amid ongoing challenges."
      },
      {
        "title": "Akums Drugs Q4 FY26: Strong Quarter Masks Full-Year Challenges",
        "link": "https://www.marketsmojo.com/news/result-analysis/akums-drugs-q4-fy26-strong-quarter-masks-full-year-challenges-3991956",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AkumsDrugsPharm_quaterlyResult_3991956.png",
        "date": "2026-05-14 20:50:40",
        "description": "Akums Drugs & Pharmaceuticals Ltd., a contract development and manufacturing organisation (CDMO) in the pharmaceutical sector, reported consolidated net profit of ₹84.61 crores for Q4 FY26, marking a robust sequential recovery of 27.58% quarter-on-quarter but a sharp year-on-year decline of 42.68%. The small-cap pharmaceutical company, with a market capitalisation of ₹8,559 crores, saw its stock trading at ₹526.40 on May 14, 2026, down 2.69% from the previous close, reflecting investor caution despite the strong quarterly performance."
      },
      {
        "title": "When is the next results date for Akums Drugs & Pharmaceuticals Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-akums-drugs-pharmaceuticals-ltd-3990188",
        "imagepath": "",
        "date": "2026-05-13 23:17:38",
        "description": "The next results date for Akums Drugs & Pharmaceuticals Ltd is scheduled for 14 May 2026...."
      },
      {
        "title": "Akums Drugs & Pharmaceuticals Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/akums-drugs-pharmaceuticals-ltd-is-rated-hold-3975892",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AkumsDrugsPharm_mojoScore_3975892.png",
        "date": "2026-05-05 10:10:02",
        "description": "Akums Drugs & Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 10 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 May 2026, providing investors with an up-to-date perspective on its performance and outlook."
      }
    ],
    "total": 195,
    "sid": "10039335",
    "stock_news_url": "https://www.marketsmojo.com/news/akums-drugs-pharmaceuticals-10039335"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
      "datetime": "18-May-2026",
      "details": "Link of Audio Recording of Investor/Analyst Conference Call",
      "source": "BSE"
    },
    {
      "caption": "Update On Disruption In Operations At Some Of The Manufacturing Sites At Haridwar",
      "datetime": "18-May-2026",
      "details": "Update on Disruption in Operations at come of the Manufacturing Sites at Haridwar",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance",
      "datetime": "16-May-2026",
      "details": "Annual Secretarial Compliance Report for the FY 2025-26",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Akums Drugs & Pharmaceuticals Ltd Shows Mildly Bullish Momentum Amid Mixed Technical Signals

2026-05-19 08:07:40

Akums Drugs & Pharmaceuticals Ltd has exhibited a subtle shift in price momentum, transitioning from a bullish to a mildly bullish technical stance. Recent indicator signals, including MACD, RSI, and moving averages, suggest a nuanced market sentiment as the stock navigates key resistance levels within the Pharmaceuticals & Biotechnology sector.

Read full news article

Akums Drugs & Pharmaceuticals Ltd: Valuation Shifts Signal Renewed Price Attractiveness

2026-05-18 08:03:18

Akums Drugs & Pharmaceuticals Ltd has witnessed a significant improvement in its valuation parameters, shifting from an 'attractive' to a 'very attractive' grade, despite a recent dip in share price. This repositioning comes amid a challenging sector environment and evolving market dynamics, prompting investors to reassess the stock’s price attractiveness relative to its peers and historical benchmarks.

Read full news article

Akums Drugs & Pharmaceuticals Ltd is Rated Hold

2026-05-16 10:10:03

Akums Drugs & Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 10 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Akums Drugs Declines 7.15%: Mixed Quarterly Results and Rising Costs Weigh on Stock

2026-05-16 10:01:53

Key Events This Week

May 11: Stock opens at Rs.539.55, down 3.17% amid broad market weakness

May 13: Share rebounds 2.45% to Rs.540.95 following stabilising quarterly outlook

May 14: Q4 FY26 results reveal strong operational metrics but margin pressures

May 15: Mixed quarterly performance reported; stock closes at Rs.517.35, down 1.72%

Week Open

Rs.557.20

Read full news article

Are Akums Drugs & Pharmaceuticals Ltd latest results good or bad?

2026-05-15 19:29:06

Akums Drugs & Pharmaceuticals Ltd's latest financial results for Q4 FY26 present a mixed picture of operational performance. The company reported a net profit of ₹84.61 crores, reflecting a quarter-on-quarter increase of 27.58%, indicating a recovery in profitability compared to the previous quarter. However, this figure represents a significant year-on-year decline of 42.68%, highlighting ongoing challenges in maintaining profitability over a longer timeframe. Net sales for the quarter stood at ₹1,157.87 crores, which was essentially flat compared to the previous quarter, showing a minor decrease of 0.15%. In contrast, year-on-year sales demonstrated a more positive trend, with a growth of 9.69% from ₹1,055.55 crores in the same quarter last year. This suggests that while sequential sales performance has stagnated, there is stable demand for the company's contract manufacturing services when viewed over a...

Read full news article

Akums Drugs & Pharmaceuticals Ltd Reports Mixed Quarterly Performance Amid Margin Pressures

2026-05-15 15:00:38

Akums Drugs & Pharmaceuticals Ltd reported a flat financial trend for the quarter ended March 2026, marking a stabilisation after previous declines. Despite this, the company demonstrated notable strength in operating margins and profitability metrics, even as net profit contracted over the nine-month period. This mixed performance has led to an upgrade in its Mojo Grade from Sell to Hold, reflecting cautious optimism amid ongoing challenges.

Read full news article

Akums Drugs Q4 FY26: Strong Quarter Masks Full-Year Challenges

2026-05-14 20:50:40

Akums Drugs & Pharmaceuticals Ltd., a contract development and manufacturing organisation (CDMO) in the pharmaceutical sector, reported consolidated net profit of ₹84.61 crores for Q4 FY26, marking a robust sequential recovery of 27.58% quarter-on-quarter but a sharp year-on-year decline of 42.68%. The small-cap pharmaceutical company, with a market capitalisation of ₹8,559 crores, saw its stock trading at ₹526.40 on May 14, 2026, down 2.69% from the previous close, reflecting investor caution despite the strong quarterly performance.

Read full news article

When is the next results date for Akums Drugs & Pharmaceuticals Ltd?

2026-05-13 23:17:38

The next results date for Akums Drugs & Pharmaceuticals Ltd is scheduled for 14 May 2026....

Read full news article

Akums Drugs & Pharmaceuticals Ltd is Rated Hold

2026-05-05 10:10:02

Akums Drugs & Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 10 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 May 2026, providing investors with an up-to-date perspective on its performance and outlook.